Lubeluzole in acute ischemic stroke: A double-blind, placebo-controlled phase II trial

Stroke

Volumn 27, Issue 1, 1996, Pages 76-81

  Diener, H C ^a   Hacke, W ^b   Hennerici, M ^c   Radberg J ^d   Hantson, L ^e,g   De Keyser, J ^f  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e JANSSEN RESEARCH FOUNDATION   (Belgium)

^f UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^g JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

cerebral ischemia; clinical trials; lubeluzole; neuroprotection

Indexed keywords

BENZOTHIAZOLE DERIVATIVE; LUBELUZOLE;

ADULT; AGED; ARTICLE; BRONCHOPNEUMONIA; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 0030069170     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.27.1.76     Document Type: Article

References (13)

1. De Ryck M, Keersmaekers R, Clincke G, Janssen M, Van Reet S. Lubeluzole, a novel benzothiazole, protects neurologic function after cerebral thrombotic stroke in rats: an apparent stereospecific effect. Soc Neurosci Abstr. 1994;20:185.
2. Scheller D, Kolb J, Szathmary S, Zacharias E, De Ryck M, Van Reempts J, Clincke B, Tegtmeier F. Extracellular changes of glutamate in the periinfarct zone: effect of lubeluzole. J Cereb Blood Flow Metab. 1995;15(suppl 1):S379.
3. Buchkremer-Ratzmann I, Witte OW. Periinfarct and transhemispheric diaschisis caused by photothrombotic infarction in rat neocortex is reduced by lubeluzole but not MK-801. J Cereb Blood Flow Metab. 1995;15(suppl 1):S38.
4. Lesage AS, De Loore KL, Osikowska-Evers B, Peeters L, Leysen JF. Lubeluzole, a novel neuroprotectant, inhibits the glutamate-activated NOS pathway. Soc Neurosci Abstr. 1994;20:185.
5. Heiss W-D, Graf R. The ischemic penumbra. Curr Opin Neurol. 1994;7:11-19.
6. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, Rorick M, Moomaw CJ, Walker M. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864-870.
7. Hantson L, De Weerdt W, De Keyser J, Diener HC, Franke C, Palm R, Van Orshoven M, Schoonderwalt H, De Klippel N, Herroelen L, Feys H. The European Stroke Scale. Stroke. 1994;25: 2215-2219.
8. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61-65.
9. Granger CV, Albrecht GL, Hamilton BB. Outcome of comprehensive medical rehabilitation: measurement by PULSES Profile and the Barthel Index. Arch Phys Med Rehabil. 1979;60:145-154.
10. Granger CV, Hamilton BR, Gresham GE, Kramer AA. The stroke rehabilitation outcome study, part II: relative merits of the total Barthel Index score and a four-item subscore in predicting patient outcomes. Arch Phys Med Rehabil. 1989;70:100-103.
11. Taub NA, Wolfe CDA, Richardson E, Burney PGJ. Predicting the disability of first-time stroke sufferers at 1 year: 12-month follow-up of a population-based cohort in southeast England. Stroke. 1994;25: 352-357.
12. Willets J, Balster RL, Leander JD. The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol Sci. 1990;11: 423-428.
13. Oppenheimer SM, Hachinski VC. The cardiac consequences of stroke. Neurol Clin. 1992;10:167-176.